Opendata, web and dolomites

OUTLIVE SIGNED

OUTLIVE: a disruptive non-invasive ultrasound therapy to treat all patients affected with aortic stenosis.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 OUTLIVE project word cloud

Explore the words cloud of the OUTLIVE project. It provides you a very rough idea of what is the project "OUTLIVE" about.

entrepreneur    body    consists    plan    time    gateway    blood    commercialisation    prize    outlive    efficacy    poor    combined    calcifies    unmet    created    cumulative    langevin    establishments    date    demonstrated    institut    guided    perfusion    winner    heart    imaging    cardiologists    function    health    investor    clinical    trust    adopters    hegp    valvosoft    changer    solutions    1bn    hospital    device    revenues    revolutionary    cardiawave    relation    life    solution    expertise    market    therapy    stenosis    unlike    standard    repair    25    medtech    aortic    ready    immense    sudden    valve    strategy    contests    intensity    death    threatening    sick    innovative    exceeding    risk    gold    thanks    replacing    ultrasounds    accelerate    untreated    world    ultrasound    age    caused    narrowing    context    invasive    mark    ce    complications    disease    dramatically    benefit    jobs    delivers    care    risks    physicians    scalable    causes    patients    treating    refine    stiffens    image    treatment    business    opening    leader    million    medical    2030    safety    game    french   

Project "OUTLIVE" data sheet

The following table provides information about the project.

Coordinator
CARDIAWAVE 

Organization address
address: 12 RUE ALBERT ROUSSEL
city: PARIS
postcode: 75017
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Total cost 3˙563˙750 €
 EC max contribution 2˙494˙625 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-01-01   to  2021-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CARDIAWAVE FR (PARIS) coordinator 2˙494˙625.00

Map

 Project objective

Aortic stenosis (AS) is a life-threatening disease caused by the narrowing of the opening of the aortic valve which is the “gateway” from the heart to the body. With age, the aortic valve calcifies and stiffens, leading to poor blood perfusion. It causes heart failure and sudden death. The only medical response to date consists in replacing the aortic valve. It is provided to very sick patients at high risk of sudden death, who represents 25% of all AS patients (6 million in Europe and US). All other affected patients remain untreated. It is an immense unmet medical need. In this context, French medtech Cardiawave has developed a revolutionary solution: Valvosoft, a very innovative real-time image guided medical device for the non-invasive treatment of all AS patients. The device delivers focused high-intensity ultrasounds which repair the aortic valve function. Unlike the current medical solutions, Valvosoft is a non-invasive treatment with low risks, complications and costs. It is a game-changer for patients, physicians and health care establishments because it dramatically changes the way of treating AS throughout the world. It should become a new gold standard: every AS patients will benefit from Valvosoft. Prize-winner of many contests, Cardiawave was created thanks to the combined expertise of an entrepreneur, the Institut Langevin, world leader in ultrasound imaging & therapy and cardiologists from HEGP hospital. The OUTLIVE project will allow Cardiawave to refine current go-to-market strategy and develop an investor ready business plan following CE-mark. Valvosoft clinical safety and efficacy will be demonstrated and reliable trust relation with early-adopters will be established. OUTLIVE will accelerate the scalable Valvosoft commercialisation and enable Cardiawave to become the future leader in non-invasive therapy with expected cumulative revenues exceeding €1.1bn by 2030 and more than 100 new European jobs created.

 Publications

year authors and title journal last update
List of publications.
2019 D. Suarez Escudero, M. Tanter, M. Pernot
FROM 2D TO 3D REAL-TIME PASSIVE CAVITATION IMAGING OF PULSED CAVITATION ULTRASOUND THERAPY
published pages: , ISSN: , DOI:
2020-01-29
2019 M. Pernot, M. C. Rémond, R. Penot, D. Ladarré, Philippe Mateo, N. Ialy-Radio, D. Suarez, Guillaume Goudot, Wojciech Kwiecinski, Michael Vion, F. Betting, Aurélien Corbel, Ana Fouquier, Sergio Cammarata, Eric Noël, Zahir Larabi, M. Tanter, E. Messas
A new therapeutic device for transthoracic treatment of calcified aortic stenosis
published pages: , ISSN: , DOI:
2020-01-29

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "OUTLIVE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "OUTLIVE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Totem Spoon (2019)

Interactive Digital Signage with emotional intelligence for smart cities

Read More  

IMPACT (2019)

Improving DNA Analysis for Correct Healthcare

Read More  

PICSOHF (2020)

PICSOHF, A minimally invasive cardiac intervention medical device to regenerate a damaged heart and extend the life of patients with Heart Failure

Read More